![]()
15
| 1 | 2007
Klinisk Biokemi i Norden
Referanser
1. Le Meur Y, et al. Therapeutic drug monitoring
of MMF: A randomized multicenter study com-
paring concentration controlled versus fixed
dose in kidney transplant recipients (World
Transplant Congress 2006 Oral Abstracts). Am
J Transplant 2006;6:343-4.
2. Mandla R, Midtvedt K, Line PD, Hartmann A,
Bergan S. Mycophenolic acid clinical phar-
macokinetics influenced by a cyclosporine C2
based immunosuppressive regimen in renal
allograft recipients. Transpl Int 2006;19:44-53.
3. Burkhart C, Heusser C, Morris RE, Raulf F, et al.
Pharmacodynamics in the development of new
immunosuppressive drugs. Ther Drug Monit
2004;26:588-92.
4. Vethe NT, Mandla R, Line PD, Midtvedt K,
Hartmann A, Bergan S. Inosine monophosphate
dehydrogenase activity in renal allograft recipi-
ents during mycophenolate treatment. Scand J
Clin Lab Invest 2006;66:31-44.
5. Vethe NT, Bergan S. Determination of ino-
sine monophosphate dehydrogenase activity in
human CD4+ cells isolated from whole blood
during mycophenolic acid therapy. Ther Drug
Monit 2006;28:608-13.
6. Glander P, Hambach P, Braun KP, Fritsche L,
et al. Pre-transplant inosine monophosphate
dehydrogenase activity is associated with cli-
nical outcome after renal transplantation. Am J
Transplant 2004;4:2045-51.
7. Ji Y, Gu J, Makhov AM, Griffith JD, Mitchell BS.
Regulation of the interaction of inosine monop-
hosphate dehydrogenase with mycophenolic
acid by GTP. J Biol Chem 2005.
8. Rambhatla L, Ram-Mohan S, Cheng JJ, Sherley
JL. Immortal DNA strand cosegregation requires
p53/IMPDH-dependent asymmetric self-rene-
wal associated with adult stem cells. Cancer Res
2005;65:3155-61.
9. Parker WB. Metabolism and antiviral activity of
ribavirin. Virus Res 2005;107:165-71.
10. Kelly LM, Lisziewicz J, Lori F. ”Virostatics” as
a potential new class of HIV drugs. Curr Pharm
Des 2004;10:4103-20.
11. Sintchak MD, Fleming MA, Futer O, Raybuck
SA, et al. Structure and mechanism of
inosine monophosphate dehydrogenase
in complex with the immunosuppressant
mycophenolic acid. Cell 1996;85:921-30.
12. Colby TD, Vanderveen K, Strickler MD,
Markham GD, Goldstein BM. Crystal struc-
ture of human type II inosine monop-
hosphate dehydrogenase: implications for
ligand binding and drug design. Proc Natl
Acad Sci U S A 1999;96:3531-6.
13. Bowne SJ, Sullivan LS, Mortimer SE,
Hedstrom L, et al. Spectrum and frequency
of mutations in IMPDH1 associated with
autosomal dominant retinitis pigmentosa
and leber congenital amaurosis. Invest
Ophthalmol Vis Sci 2006;47:34-42.
14. Gan L, Seyedsayamdost MR, Shuto S,
Matsuda A, et al. The immunosuppressive
agent mizoribine monophosphate forms
a transition state analogue complex with
inosine monophosphate dehydrogenase.
Biochemistry 2003;42:857-63.
15. Beevers RE, Buckley GM, Davies N, Fraser
JL, et al. Novel indole inhibitors of IMPDH
from fragments: synthesis and initial struc-
ture-activity relationships. Bioorg Med
Chem Lett 2006;16:2539-42.
Forsiden:
Human type II IMPDH tetramer
with bound dinucleotide analogue SAD (cir-
cled, red) and substrate analogue 6-C1-IMP
(circled,green). The dinucleotide binds at the
monomer-monomer interface (dotted lines).
The following structures are illustrated: cata-
lytic b-barrel domain (blue), flanking domain
(magenta), active site loop (yellow) and active
site flap fragments (white).
6-C1-IMP, 6-chloropurine riboside 5’-monop-
hosphate; SAD, selenazole-4-carboxamide ade-
nine dinucleotide (ref. 12).
© 1999, National Academy of Sciences, USA.
